Ocular Therapeut SEC Filings

Officer sale under pre-set plan: An officer of Ocular Therapeutix, Inc. (OCUL) reported the sale of 9,653 shares of common stock under a durable automatic sale instruction intended to satisfy tax withholding on RSU vesting. The transactions were effected on 10/02/2025 as non‑discretionary sales tied to the reporting person’s sell‑to‑cover election for restricted stock units that vested on 10/01/2025.

The filing reports a weighted average sale price of $11.03 (trade prices ranged between $10.99 and $11.0697) and shows the reporting person retained beneficial ownership of 194,440 shares after the transactions. The form was signed by an attorney‑in‑fact and discloses the sale was pursuant to a plan adopted on 04/09/2024.

Insider sale to cover taxes on vested RSUs: The Chief Scientific Officer, Jeffrey S. Heier, reported sales of 10,502 shares of Ocular Therapeutix common stock on 10/02/2025 under a pre-existing automatic sale instruction. The disposals were non-discretionary sell-to-cover transactions tied to the vesting of restricted stock units on 10/01/2025.

Those shares were sold in multiple trades at prices ranging from $10.99 to $11.0866, with a reported weighted-average price of $11.04. After the sales, the reporting person beneficially owned 249,409 shares directly.

Ocular Therapeutix (OCUL) filing a Form 144 notifies the proposed sale of 10,502 common shares with an aggregate market value of $115,889.57. The shares were acquired on 10/01/2025 through restricted stock vesting under a registered plan, and the proposed approximate sale date is 10/02/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filing reports 173,995,221 shares outstanding for the issuer. It also discloses a recent sale by the same person: 3,063 shares sold on 08/25/2025 for $36,882.81. The filer affirms they are not aware of any undisclosed material adverse information.

OCULAR THERAPEUTIX, INC. (OCUL) filed a Form 144 notifying a proposed sale of 9,653 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $106,516.03. The sale is scheduled approximately for 10/02/2025 on NASDAQ. The shares were acquired on 10/01/2025 as restricted stock vesting under a registered plan and payment (if any) is noted as Not Applicable. The filing names Peter Kazuo Kaiser as a seller who previously sold 3,011 shares on 08/25/2025 for $36,252.74. The notice includes the seller's representation that they are not aware of undisclosed material adverse information about the issuer.

Ocular Therapeutix, Inc. is offering 37,909,018 shares of common stock at a market reference price of $12.53 per share, with expected delivery on or about October 1, 2025. After the offering the company would have 210,834,407 shares outstanding and expects net proceeds of approximately $445.9 million. As of June 30, 2025, the company reported $391.1 million in cash and cash equivalents and says the combined cash resources are expected to fund planned clinical and pre-commercial activities into 2028 under its current operating plan.

Proceeds are earmarked to fund AXPAXLI development and clinical programs including the SOL-X open-label extension and the HELIOS-2 and HELIOS-3 Phase 3 trials, manufacturing and infrastructure investments, pre-commercialization activities for AXPAXLI if approved, and general corporate purposes. The company discloses immediate dilution to new investors of $8.96 per share versus the offering price and highlights lock-up agreements and customary underwriting arrangements for the offering.

Ocular Therapeutix, Inc. entered into an underwriting agreement for an underwritten public offering of 37,909,018 shares of its common stock at an offering price of $12.53 per share, with underwriters purchasing at $11.7782 per share. The company expects to receive approximately $445.9 million in net proceeds after underwriting discounts, commissions and expenses. The shares are being issued under an automatically effective shelf registration statement on Form S-3, with closing expected on or about October 1, 2025, subject to customary conditions. Based on its current operating plan, including DEXTENZA product sales and observing a $20.0 million minimum liquidity covenant, the company believes its existing cash and cash equivalents plus these proceeds will fund planned operating expenses, debt service and capital expenditures into 2028, though this excludes full commercialization expenses for AXPAXLI and is based on assumptions that may change.

Ocular Therapeutix reported progress and plans for its AXPAXLI (OTX-TKI) ophthalmology program, including multiple Phase 3 trials in wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR), plus a new U.S. patent allowance. In wet AMD, the company’s registrational SOL-1 Phase 3 trial has completed randomization of 344 subjects, is being run under an FDA special protocol assessment, shows retention above 95%, and has not generated new or unexpected safety signals to date, with topline results expected in the first quarter of 2026. A second Phase 3 trial, SOL-R, has completed enrollment and is designed to show non-inferiority to on-label aflibercept dosing, with topline data expected in the first half of 2027 and a planned follow-on long-term extension trial (SOL-X).

For NPDR, the company plans two Phase 3 studies, HELIOS-2 and HELIOS-3, using a diabetic retinopathy severity score–based primary endpoint at Week 52, and has FDA agreement under a special protocol assessment for the HELIOS-2 design. The company also received a notice of allowance for a U.S. patent with claims covering methods of treating ocular diseases with AXPAXLI, which is expected to provide protection into 2044, absent any extensions.

Ocular Therapeutix (OCUL) filed a Form S-3 shelf registration dated September 30, 2025 to offer, from time to time, debt securities, common stock, preferred stock, depositary shares, warrants, and units. The prospectus describes general terms; specific offering terms will appear in prospectus supplements. OCUL's common stock trades on The Nasdaq Global Market under the symbol OCUL. Proceeds are intended for general corporate purposes including R&D, clinical trials, regulatory submissions, commercialization, manufacturing, acquisitions, debt repayment and working capital. The filing incorporates by reference recent annual and quarterly reports, certain current reports and an updated capital stock description. The prospectus discloses key forward-looking programs including Phase 3 SOL-1 and SOL-R trials for AXPAXLI (OTX-TKI), a Phase 2 trial for OTX-TIC, and commercial activity for DEXTENZA, an FDA-approved product.

Pravin Dugel, Executive Chairman, President and CEO of Ocular Therapeutix, Inc. (OCUL), reported intra-family transfers on Form 4. On 09/09/2025 he transferred 49,754 shares of the company's common stock to his spouse for no consideration and, on the same date, a corresponding entry shows 49,754 shares recorded as acquired indirectly by spouse. After the reported transactions, Mr. Dugel directly owned 3,177,490 shares and had indirect ownership stakes of 250,361 shares through the Pravin Dugel 2024 Irrevocable Trust and 49,754 shares held by his spouse. The Form 4 was signed by an attorney-in-fact on 09/11/2025.